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Naturally occurring or induced Ad-specific neutralizing
antibodies impeded the activity of recombinant Ad5-based
vectors with E1 deletions. An improved Ad vector with
deletions of the E1 and the E2b regions (Ad5 [E1-, E2b-]),
the latter encoding the DNA polymerase and the pre-
terminal protein, with significantly diminished late phase
viral protein expression, were hypothesized to avoid
immunological clearance and induce more potent immune
responses against the encoded tumor antigen transgene in
Ad-immune hosts. In the present phase I/II study, cohorts
of patients with advanced metastatic colorectal cancer
(mCRC) were immunized with escalating doses of Ad5
[E1-, E2b-]-CEA(6D). The carcinoembryonic antigen
(CEA) transgene employed contains a modification
(CAP1-6D) designed to enhance CTL stimulation. CEA-
specific CMI responses were observed despite the
presence of pre-existing Ad5 immunity in a majority
(61.3%) of patients. Long-term follow-up in some of the
patients reveled a waning of the induced CEA directed
immune responses at around 6 months. Importantly, there
was minimal toxicity, and overall patient survival (48% at
12 months) was similar regardless of pre-existing Ad5
neutralizing antibody titers. Our patient demographics,
albeit limited in size, we similar with previously published
studies of patients with chemotherapy-refractory mCRC.
Of particular interest is the observation that treated
mCRC patients in our study exhibited favorable survival
probability. The results demonstrate that, in cancer
patients, the novel Ad5 [E1-, E2b-] gene delivery platform
generates significant CMI responses to the tumor antigen
CEA in the setting of both naturally acquired and immuni-
zation-induced Ad5-specific immunity.
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